Clinical characteristics of patients included in the autologous NK cell study
| Patient . | Dx age in y (gender) . | Treatment (duration) . | Response at time of NK cell isolation* . | NK cells (% of lymphs) . | CD123 expression . | |
|---|---|---|---|---|---|---|
| % CD123+ (MFI) [CD34+] . | % CD123+ (MFI) [CD34+/CD38–] . | |||||
| CP-CML 1 | 48 (M) | Dasatinib (12 mo) | CMR | 6.1 | 56.2 (2.6) | 10.7 (1.7) |
| CP-CML 2 | 70 (M) | Imatinib (28 mo) | MMR | 7.9 | 67.2 (2.9) | 15.1 (2.0) |
| CP-CML 3 | 64 (M) | Imatinib (10 mo) | CCyR | 6.8 | 48.7 (2.1) | 52.7 (2.1) |
| CP-CML 4 | 42 (M) | Imatinib (26 mo) | CCyR | 14.4 | 69.3 (2.5) | n. d. |
| CP-CML 5 | 64 (F) | Nilotinib (6 mo) | MMR | 5.1 | 70.1 (3.3) | 43.8 (2.6) |
| BC-CML 1 | 55 (F) | Dasatinib (48 mo) | CMR | 4.1 | 89.9 (6.7) | 84.3 (5.6) |
| Patient . | Dx age in y (gender) . | Treatment (duration) . | Response at time of NK cell isolation* . | NK cells (% of lymphs) . | CD123 expression . | |
|---|---|---|---|---|---|---|
| % CD123+ (MFI) [CD34+] . | % CD123+ (MFI) [CD34+/CD38–] . | |||||
| CP-CML 1 | 48 (M) | Dasatinib (12 mo) | CMR | 6.1 | 56.2 (2.6) | 10.7 (1.7) |
| CP-CML 2 | 70 (M) | Imatinib (28 mo) | MMR | 7.9 | 67.2 (2.9) | 15.1 (2.0) |
| CP-CML 3 | 64 (M) | Imatinib (10 mo) | CCyR | 6.8 | 48.7 (2.1) | 52.7 (2.1) |
| CP-CML 4 | 42 (M) | Imatinib (26 mo) | CCyR | 14.4 | 69.3 (2.5) | n. d. |
| CP-CML 5 | 64 (F) | Nilotinib (6 mo) | MMR | 5.1 | 70.1 (3.3) | 43.8 (2.6) |
| BC-CML 1 | 55 (F) | Dasatinib (48 mo) | CMR | 4.1 | 89.9 (6.7) | 84.3 (5.6) |
CCyR, complete cytogenetic response; Dx, diagnosis; F, female; lymphs, lymphocytes; M, male; n. d., not determined.
CCyR (no Ph+ metaphases); CMR (undetectable BCR-ABL messenger RNA); MMR (≥3 log reduction of BCR-ABL messenger RNA).